HCST and neoplasm: In conclusion, this work provides evidence for the first time that CD33 functions as an inhibitory receptor preferentially for the NKG2D/DAP10 pathway, with implications in the regulation of ongoing immune responses against tumor and infected cells, in protecting self-cells and probably in avoiding autoimmunity.